Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards

Rhea-AI Summary

Clearmind Medicine Inc. (Nasdaq: CMND, CSE: CMND, FSE: CWY) has regained compliance with the minimum bid price requirement set forth by Nasdaq, ensuring that its common shares will continue to be listed and traded on Nasdaq.

Nasdaq Has Informed the Company That a Bid Price Deficiency of its Common Shares Has Been Cured

Tel Aviv, Israel / Vancouver, Canada, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that on December 12, 2023 it received a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires the Company's common shares to maintain a minimum bid price of $1.00 per share.

The Nasdaq staff made this determination of compliance after the closing bid price of the Company's common shares was at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1) and Nasdaq considers the prior bid price deficiency matter now closed.

As a result, the scheduled hearing before the Nasdaq Listing Qualifications Hearings Panel requested by the Company to stay the suspension of the Company’s securities from Nasdaq was canceled. The Company is now in compliance with all applicable listing standards and its common shares will continue to be listed and traded on Nasdaq.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of fourteen patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY.”

For further information visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F filed with the SEC on February 6, 2023. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

What is the latest announcement from Clearmind Medicine Inc. (CMND)?

Clearmind Medicine Inc. (Nasdaq: CMND, CSE: CMND, FSE: CWY) has regained compliance with the minimum bid price requirement set forth by Nasdaq, ensuring that its common shares will continue to be listed and traded on Nasdaq.

What is the significance of the Nasdaq bid price deficiency being cured for Clearmind Medicine Inc. (CMND)?

The bid price deficiency being cured means that Clearmind Medicine Inc. (CMND) has regained compliance with the minimum bid price requirement set forth by Nasdaq, ensuring that its common shares will continue to be listed and traded on Nasdaq.

What does the compliance with Nasdaq Listing Rule 5550(a)(2) mean for Clearmind Medicine Inc. (CMND)?

The compliance with Nasdaq Listing Rule 5550(a)(2) means that Clearmind Medicine Inc. (CMND) has maintained a minimum bid price of $1.00 per share for the prior 10 consecutive business days, ensuring that its common shares will continue to be listed and traded on Nasdaq.

What is the impact of the Nasdaq determination of compliance on Clearmind Medicine Inc. (CMND)?

The Nasdaq determination of compliance means that Clearmind Medicine Inc. (CMND) has regained compliance with all applicable listing standards, ensuring that its common shares will continue to be listed and traded on Nasdaq.